Iptacopan
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Iptacopan, sold under the brand name Fabhalta, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria. It is a complement factor B inhibitor that was developed by Novartis. It is taken by mouth. Iptacopan was approved for medical use in the United States in December 2023, and in the European Union in May 2024. The US Food and Drug Administration considers it to be a first-in-class medication.
Iptacopan, sold under the brand name Fabhalta, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria. It is a complement factor B inhibitor that was developed by Novartis. It is taken by mouth. Iptacopan was approved for medical use in the United States in December 2023, and in the European Union in May 2024. The US Food and Drug Administration considers it to be a first-in-class medication.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1360269879 under CC BY-SA 4.0; modifications have been made.